vs
Side-by-side financial comparison of R F INDUSTRIES LTD (RFIL) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
R F INDUSTRIES LTD is the larger business by last-quarter revenue ($22.7M vs $18.6M, roughly 1.2× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 0.8%, a 65.0% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 22.9%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 29.8%).
Tootsie Roll Industries is an American manufacturer of confectionery based in Chicago, Illinois. Its best-known products include the namesake Tootsie Rolls and Tootsie Pops. Tootsie Roll Industries currently markets its brands internationally in Canada, Mexico, and over 75 other countries.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
RFIL vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.7M | $18.6M |
| Net Profit | $173.0K | $12.3M |
| Gross Margin | 36.8% | — |
| Operating Margin | 4.0% | 56.3% |
| Net Margin | 0.8% | 65.7% |
| Revenue YoY | 22.9% | 1808.5% |
| Net Profit YoY | 172.7% | 376.5% |
| EPS (diluted) | $0.01 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.7M | $18.6M | ||
| Q3 25 | $19.8M | $334.0K | ||
| Q2 25 | $18.9M | $1.4M | ||
| Q1 25 | $19.2M | $257.0K | ||
| Q4 24 | $18.5M | $977.0K | ||
| Q3 24 | $16.8M | $660.0K | ||
| Q2 24 | $16.1M | $736.0K | ||
| Q1 24 | $13.5M | $1.4M |
| Q4 25 | $173.0K | $12.3M | ||
| Q3 25 | $392.0K | $-8.6M | ||
| Q2 25 | $-245.0K | $-6.9M | ||
| Q1 25 | $-245.0K | $-5.4M | ||
| Q4 24 | $-238.0K | — | ||
| Q3 24 | $-705.0K | $-2.8M | ||
| Q2 24 | $-4.3M | $-14.5M | ||
| Q1 24 | $-1.4M | $411.0K |
| Q4 25 | 36.8% | — | ||
| Q3 25 | 34.0% | — | ||
| Q2 25 | 31.5% | — | ||
| Q1 25 | 29.8% | — | ||
| Q4 24 | 31.3% | — | ||
| Q3 24 | 29.5% | — | ||
| Q2 24 | 29.9% | — | ||
| Q1 24 | 24.5% | — |
| Q4 25 | 4.0% | 56.3% | ||
| Q3 25 | 3.6% | -2516.5% | ||
| Q2 25 | 0.6% | -701.0% | ||
| Q1 25 | 0.3% | -3350.2% | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | -2.5% | -1563.6% | ||
| Q2 24 | -2.6% | -1255.0% | ||
| Q1 24 | -15.5% | -692.5% |
| Q4 25 | 0.8% | 65.7% | ||
| Q3 25 | 2.0% | -2572.2% | ||
| Q2 25 | -1.3% | -504.8% | ||
| Q1 25 | -1.3% | -2097.7% | ||
| Q4 24 | -1.3% | — | ||
| Q3 24 | -4.2% | -425.5% | ||
| Q2 24 | -26.7% | -1964.4% | ||
| Q1 24 | -10.1% | 29.9% |
| Q4 25 | $0.01 | $0.25 | ||
| Q3 25 | $0.04 | $-0.17 | ||
| Q2 25 | $-0.02 | $-0.14 | ||
| Q1 25 | $-0.02 | $-0.11 | ||
| Q4 24 | $-0.02 | — | ||
| Q3 24 | $-0.07 | $-0.06 | ||
| Q2 24 | $-0.41 | $-0.30 | ||
| Q1 24 | $-0.13 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $35.2M | $49.4M |
| Total Assets | $73.0M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | $40.0M | ||
| Q3 25 | $3.0M | $37.9M | ||
| Q2 25 | $3.6M | $44.8M | ||
| Q1 25 | $1.3M | $40.6M | ||
| Q4 24 | $839.0K | $59.3M | ||
| Q3 24 | $1.8M | $68.8M | ||
| Q2 24 | $1.4M | $73.0M | ||
| Q1 24 | $4.5M | $80.2M |
| Q4 25 | $35.2M | $49.4M | ||
| Q3 25 | $34.8M | $36.4M | ||
| Q2 25 | $34.2M | $44.5M | ||
| Q1 25 | $34.2M | $50.5M | ||
| Q4 24 | $34.1M | $55.1M | ||
| Q3 24 | $34.1M | $58.5M | ||
| Q2 24 | $34.6M | $60.4M | ||
| Q1 24 | $38.7M | $74.1M |
| Q4 25 | $73.0M | $59.0M | ||
| Q3 25 | $73.2M | $51.1M | ||
| Q2 25 | $72.7M | $60.7M | ||
| Q1 25 | $70.4M | $67.9M | ||
| Q4 24 | $71.0M | $90.6M | ||
| Q3 24 | $71.9M | $99.0M | ||
| Q2 24 | $72.8M | $107.8M | ||
| Q1 24 | $79.1M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | $18.4M |
| Free Cash FlowOCF − Capex | $2.0M | — |
| FCF MarginFCF / Revenue | 9.0% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | 12.13× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $4.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $18.4M | ||
| Q3 25 | $-311.0K | $-8.7M | ||
| Q2 25 | $2.2M | $-7.5M | ||
| Q1 25 | $601.0K | $-7.5M | ||
| Q4 24 | $-244.0K | $-24.0M | ||
| Q3 24 | $2.4M | $765.0K | ||
| Q2 24 | $197.0K | $-10.9M | ||
| Q1 24 | $840.0K | $-4.0M |
| Q4 25 | $2.0M | — | ||
| Q3 25 | $-419.0K | — | ||
| Q2 25 | $2.2M | — | ||
| Q1 25 | $574.0K | — | ||
| Q4 24 | $-418.0K | — | ||
| Q3 24 | $2.1M | — | ||
| Q2 24 | $28.0K | — | ||
| Q1 24 | $697.0K | — |
| Q4 25 | 9.0% | — | ||
| Q3 25 | -2.1% | — | ||
| Q2 25 | 11.4% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 5.2% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 1.1% | — |
| Q4 25 | 12.13× | 1.50× | ||
| Q3 25 | -0.79× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RFIL
| US | $20.9M | 92% |
| Non Us | $1.8M | 8% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
